OKYO Pharma's OK-101 Asset Named Urcosimod
Ticker: OKYO · Form: 6-K · Filed: Feb 12, 2025 · CIK: 1849296
| Field | Detail |
|---|---|
| Company | Okyo Pharma LTD (OKYO) |
| Form Type | 6-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-update, drug-development, pharmaceutical
TL;DR
OKYO Pharma's lead drug OK-101 is now officially 'urcosimod' - big step for the company.
AI Summary
On February 12, 2025, OKYO Pharma Ltd announced that its lead asset, OK-101, has been officially assigned the United States Adopted Name (USAN) "urcosimod". This designation is a significant step in the development and potential commercialization of the drug.
Why It Matters
The official USAN name 'urcosimod' for OK-101 is a key regulatory milestone, facilitating further clinical development and potential market entry for OKYO Pharma's lead drug candidate.
Risk Assessment
Risk Level: low — This filing is an informational update regarding a drug name assignment, which is a standard regulatory process and does not inherently introduce new financial or operational risks.
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- OK-101 (drug_candidate) — Lead asset
- urcosimod (drug_name) — United States Adopted Name (USAN) for OK-101
- February 12, 2025 (date) — Date of announcement
FAQ
What is the significance of OK-101 being assigned the USAN name 'urcosimod'?
The assignment of the USAN name 'urcosimod' to OK-101 is a regulatory milestone that facilitates its further development and potential commercialization.
When did OKYO Pharma Ltd announce the USAN name assignment for OK-101?
OKYO Pharma Ltd announced the USAN name assignment for OK-101 on February 12, 2025.
What is the exact name of the lead asset of OKYO Pharma Ltd?
The lead asset of OKYO Pharma Ltd is OK-101.
What does USAN stand for?
USAN stands for United States Adopted Name.
What type of company is OKYO Pharma Ltd?
OKYO Pharma Ltd is a company in the Biological Products sector, specifically not including diagnostic substances.
Filing Stats: 333 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2025-02-12 07:00:31
Filing Documents
- form6-k.htm (6-K) — 23KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 21KB
- 0001493152-25-006035.txt ( ) — 69KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: February 12, 2025 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated February 12, 2025 4